Literature DB >> 21234778

Reversible posterior leukoencephalopathy syndrome in a patient with thrombotic thrombocytopenic purpura.

Paolo Aridon1, Paolo Ragonese, Maria Antonietta Mazzola, Gerlando Quintini, Marianna Lo Re, Simona Talamanca, Valeria Terruso, Marco D'Amelio, Giovanni Savettieri.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is an autoimmune disorder characterised by fever, microangiopathic haemolytic anaemia, renal insufficiency, and thrombocytopenia. Neurological involvement, a prominent component of TTP, is characterised by a variety of brain lesions which include reversible cerebral oedema or magnetic resonance imaging (MRI) features of reversible posterior leukoencephalopathy syndrome (RPLS). TTP is frequently associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13.Here, we report a case of TTP with severe acute encephalopathy. Posterior leukoencephalopathy and brainstem oedema with triventricular hydrocephalus were observed on MRI. The low activity of ADAMTS13 was not observed and ADAMTS-13 antibodies were absent. Neurological symptoms and patient's condition were completely resolved by plasma exchange therapy in addition to high dose of methylprednisolone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21234778     DOI: 10.1007/s10072-010-0465-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  10 in total

1.  Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome.

Authors:  Domenica Caramazza; Gerlando Quintini; Ignazio Abbene; Lucio Lo Coco; Alessandra Malato; Rosa Di Trapani; Giorgia Saccullo; Giuseppina Pizzo; Roberto Palazzolo; Rita Barone; Giuseppina Mazzola; Sergio Rizzo; Paolo Ragonese; Paolo Aridon; Vincenzo Abbadessa; Sergio Siragusa
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

2.  Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura.

Authors:  Tamika M Burrus; Eelco F M Wijdicks; Alejandro A Rabinstein
Journal:  Neurology       Date:  2009-07-07       Impact factor: 9.910

3.  Thrombotic thrombocytopenic purpura: brain CT and MRI findings in 12 patients.

Authors:  R Bakshi; Z A Shaikh; V E Bates; P R Kinkel
Journal:  Neurology       Date:  1999-04-12       Impact factor: 9.910

Review 4.  A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura.

Authors:  S J Brunskill; A Tusold; S Benjamin; S J Stanworth; M F Murphy
Journal:  Transfus Med       Date:  2007-02       Impact factor: 2.019

Review 5.  Atypical presentations of thrombotic thrombocytopenic purpura: a review.

Authors:  Ravi Sarode
Journal:  J Clin Apher       Date:  2009       Impact factor: 2.821

Review 6.  Posterior reversible encephalopathy syndrome.

Authors:  John H Pula; Eric Eggenberger
Journal:  Curr Opin Ophthalmol       Date:  2008-11       Impact factor: 3.761

7.  Atypical reversible posterior leukoencephalopathy syndrome in thrombotic thrombocytopenic purpura.

Authors:  Demet Funda Bas; Kader Karli Oguz; Mehmet Akif Topcuoglu
Journal:  Intern Med       Date:  2008-11-04       Impact factor: 1.271

Review 8.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

9.  Posterior reversible encephalopathy syndrome: a report of a case with atypical features.

Authors:  J N Pratap; J F Down
Journal:  Anaesthesia       Date:  2008-08-19       Impact factor: 6.955

10.  Clinical spectrum of reversible posterior leukoencephalopathy syndrome.

Authors:  Vivien H Lee; Eelco F M Wijdicks; Edward M Manno; Alejandro A Rabinstein
Journal:  Arch Neurol       Date:  2008-02
  10 in total
  3 in total

1.  Corticosteroid therapy and severity of vasogenic edema in posterior reversible encephalopathy syndrome.

Authors:  Neal S Parikh; Andrew D Schweitzer; Robert J Young; Ashley E Giambrone; John Lyo; Sasan Karimi; Anna Knobel; Ajay Gupta; Babak B Navi
Journal:  J Neurol Sci       Date:  2017-06-29       Impact factor: 3.181

Review 2.  Reversible obstructive hydrocephalus from hypertensive encephalopathy.

Authors:  Abhay Kumar; Salah G Keyrouz; Jon T Willie; Rajat Dhar
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

Review 3.  Imaging in sepsis-associated encephalopathy--insights and opportunities.

Authors:  Daniel J Stubbs; Adam K Yamamoto; David K Menon
Journal:  Nat Rev Neurol       Date:  2013-09-03       Impact factor: 42.937

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.